ValuEngine downgraded shares of Champions Oncology (NASDAQ:CSBR) from a hold rating to a sell rating in a research report report published on Wednesday morning.
Champions Oncology (CSBR) traded down $0.14 during trading hours on Wednesday, hitting $3.54. The stock had a trading volume of 48,400 shares, compared to its average volume of 53,048. Champions Oncology has a 1 year low of $2.09 and a 1 year high of $4.79.
Champions Oncology (NASDAQ:CSBR) last released its earnings results on Thursday, September 14th. The biotechnology company reported ($0.06) earnings per share for the quarter. The company had revenue of $5.03 million for the quarter. Champions Oncology had a negative net margin of 29.87% and a negative return on equity of 338.01%.
An institutional investor recently raised its position in Champions Oncology stock. GRT Capital Partners L.L.C. lifted its holdings in shares of Champions Oncology Inc (NASDAQ:CSBR) by 70.6% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 41,064 shares of the biotechnology company’s stock after buying an additional 17,000 shares during the period. GRT Capital Partners L.L.C. owned about 0.37% of Champions Oncology worth $106,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 38.04% of the company’s stock.
WARNING: This piece was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thelincolnianonline.com/2017/12/07/champions-oncology-csbr-downgraded-by-valuengine-to-sell.html.
Champions Oncology Company Profile
Champions Oncology, Inc is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.
Receive News & Ratings for Champions Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.